Back to News
Market Impact: 0.3
COSCIENS Acquires Nualtis For $15 Mln; Raises Up To $20 Mln Via Convertible Debentures
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechTechnology & Innovation
COSCIENS Biopharma announced the acquisition of Montreal-based Nualtis Corp., a specialty pharmaceutical technology company focused on proprietary oral thin-film drug-delivery technologies. The transaction expands COSCIENS' drug-delivery technology capabilities, though the article excerpt provides no purchase price, financial terms, or expected earnings impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CSCI0.65
More News
- Nvidia in talks to invest up to $10 billion in Anthropic IPO
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Exclusive-Nvidia in talks to invest in Anthropic’s mega IPO, sources say
- Why ACV Stock Rocketed 44% Higher Today
- Surging cloud revenue boosted Oracle’s quarterly results. Here’s what analysts are saying
- Oracle jumps 6% after reporting 30% revenue growth fueled by AI cloud demand